# Tenvie Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tenvie-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.tenvie.com
- Total disclosed funding: $200M
- Latest round: Series A (Jan 8, 2025)
- Investors on record: 3

## About

Based in California, US, and founded in 2025 by co-founders Brian Cuneo, Tony Estrada, and Tenvie Therapeutics, Inc., developer of small molecule therapies that target critical drivers of disease, including inflammation, metabolic dysfunction, and lysosomal dysfunction. In January 2025, Tenvie Therapeutics, Inc. raised USD 200 million in venture funding co-led by investors ARCH Venture Partners, F-Prime Capital, and Mubadala Capital. 

Tenvie offers an advancing, comprehensive pipeline of small molecules to tackle a range of diseases affecting both the CNS and peripheral systems. The solution penetrant small molecules that cross the blood-brain barrier target diseases affecting the brain and nervous system and cross the blood-brain barrier effectively, as well as precision molecules that are restricted to peripheral areas of the body to address other conditions. Tenvie’s pipeline includes a variety of small molecules that are in various stages of development, targeting key drivers of disease progression in the CNS and peripheral systems. The therapeutic focus includes three primary disease mechanisms: inflammation, metabolic dysfunction, and lysosomal dysfunction.

The company will use the January 2025 funding to support its business growth and development strategies.

## Funding rounds

- Series A, Jan 8, 2025, $200M — ARCH Venture Partners, F-Prime Capital, Mubadala Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series A